Enterprise information has been authenticated 
Autobio Diagnostics Co., Ltd (Hereinafter called Autobio) was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou.
Autobio specializes in R & D, production, marketing, and service of clinical diagnostic products, especially covering immunoassay, microbiology, and biochemistry fields. Meanwhile, Autobio is also actively planning developments in the field of molecular diagnostics and provides a comprehensive solution for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, and is the first IVD manufacturer listed on the main board in Shanghai, China. In 2024, Autobio's revenue achieved RMB 4471 million.
Autobio highly values the importance of product R&D and technological innovation
The annual average R&D investment exceeds 15% in the last year; Autobio focuses on team building, with over one-third of R&D talents among all employees; Compared with the international advanced experience, Autobio applies strict research and development process management; Focusing on the research and development of core raw materials, Autobio has created a diagnostic antibody library for tens of thousands of antigen epitopes, with over 73% self-supply for antigen and antibody, which ensures the stability and safety of supply. Autobio has become one of the leading companies with the most registered products and the most comprehensive product catalog.